Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 283

1.

Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?

Neuhoff S, Tucker GT.

Br J Clin Pharmacol. 2018 Jul;84(7):1620-1621. doi: 10.1111/bcp.13538. Epub 2018 Feb 21. No abstract available.

2.

Development and applications of a physiologically-based model of paediatric oral drug absorption.

Johnson TN, Bonner JJ, Tucker GT, Turner DB, Jamei M.

Eur J Pharm Sci. 2018 Mar 30;115:57-67. doi: 10.1016/j.ejps.2018.01.009. Epub 2018 Jan 5.

PMID:
29309876
3.

Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.

Polasek TM, Tucker GT, Sorich MJ, Wiese MD, Mohan T, Rostami-Hodjegan A, Korprasertthaworn P, Perera V, Rowland A.

Br J Clin Pharmacol. 2018 Mar;84(3):462-476. doi: 10.1111/bcp.13480. Epub 2018 Jan 11.

4.

Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.

Miners JO, Chau N, Rowland A, Burns K, McKinnon RA, Mackenzie PI, Tucker GT, Knights KM, Kichenadasse G.

Biochem Pharmacol. 2017 Apr 1;129:85-95. doi: 10.1016/j.bcp.2017.01.002. Epub 2017 Jan 6.

PMID:
28065859
5.

Personalized Drug Dosage - Closing the Loop.

Tucker GT.

Pharm Res. 2017 Aug;34(8):1539-1543. doi: 10.1007/s11095-016-2076-0. Epub 2016 Dec 9. Review.

6.

Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions.

Burt HJ, Neuhoff S, Almond L, Gaohua L, Harwood MD, Jamei M, Rostami-Hodjegan A, Tucker GT, Rowland-Yeo K.

Eur J Pharm Sci. 2016 Jun 10;88:70-82. doi: 10.1016/j.ejps.2016.03.020. Epub 2016 Mar 25.

7.

In Vitro Characterization of the Human Liver Microsomal Kinetics and Reaction Phenotyping of Olanzapine Metabolism.

Korprasertthaworn P, Polasek TM, Sorich MJ, McLachlan AJ, Miners JO, Tucker GT, Rowland A.

Drug Metab Dispos. 2015 Nov;43(11):1806-14. doi: 10.1124/dmd.115.064790. Epub 2015 Sep 1.

PMID:
26329789
8.

Erratum to: A Re-evaluation and Validation of Ontogeny Functions for Cytochrome P450 1A2 and 3A4 Based on In Vivo Data.

Salem F, Johnson TN, Abduljalil K, Tucker GT, Rostami-Hodjegan A.

Clin Pharmacokinet. 2015 Jun;54(6):671. doi: 10.1007/s40262-015-0284-0. No abstract available.

PMID:
25968247
9.

Does age affect gastric emptying time? A model-based meta-analysis of data from premature neonates through to adults.

Bonner JJ, Vajjah P, Abduljalil K, Jamei M, Rostami-Hodjegan A, Tucker GT, Johnson TN.

Biopharm Drug Dispos. 2015 May;36(4):245-57. doi: 10.1002/bdd.1937. Epub 2015 Feb 12.

10.

A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data.

Salem F, Johnson TN, Abduljalil K, Tucker GT, Rostami-Hodjegan A.

Clin Pharmacokinet. 2014 Jul;53(7):625-36. doi: 10.1007/s40262-014-0140-7. Erratum in: Clin Pharmacokinet. 2015 Jun;54(6):671.

PMID:
24671884
11.

Physiologically based pharmacokinetic-pharmacodynamic modeling to the rescue: understanding how resuscitation from local anesthetic overdose with lipid emulsions works.

Tucker GT.

Anesthesiology. 2014 Apr;120(4):795-6. doi: 10.1097/ALN.0000000000000143. No abstract available.

PMID:
24469262
12.
13.

Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.

Barter ZE, Tucker GT, Rowland-Yeo K.

Clin Pharmacokinet. 2013 Dec;52(12):1085-100. doi: 10.1007/s40262-013-0089-y.

PMID:
23818090
14.

Comment on the article "physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions".

Neuhoff S, Tucker GT.

Pharm Res. 2013 Jun;30(6):1467-8. doi: 10.1007/s11095-013-0988-5. Epub 2013 Mar 16. No abstract available.

PMID:
23504339
15.

Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment.

Shiran MR, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT, Rostami-Hodjegan A.

J Clin Psychopharmacol. 2012 Oct;32(5):666-71. doi: 10.1097/JCP.0b013e3182664ecd.

PMID:
22926601
16.

Impact of the pharmaceutical sciences on health care: a reflection over the past 50 years.

Rowland M, Noe CR, Smith DA, Tucker GT, Crommelin DJ, Peck CC, Rocci ML Jr, Besançon L, Shah VP.

J Pharm Sci. 2012 Nov;101(11):4075-99. doi: 10.1002/jps.23295. Epub 2012 Aug 21.

PMID:
22911654
17.

Research priorities in pharmacokinetics.

Tucker GT.

Br J Clin Pharmacol. 2012 Jun;73(6):924-6. doi: 10.1111/j.1365-2125.2012.04238.x.

18.

Dr. Daniel C. Moore--in appreciation.

Tucker GT, Mather LE.

Reg Anesth Pain Med. 2012 Mar-Apr;37(2):236. doi: 10.1097/AAP.0b013e3182460755. No abstract available.

PMID:
22354073
19.

Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.

Rowland Yeo K, Walsky RL, Jamei M, Rostami-Hodjegan A, Tucker GT.

Eur J Pharm Sci. 2011 Jun 14;43(3):160-73. doi: 10.1016/j.ejps.2011.04.008. Epub 2011 Apr 20.

PMID:
21540107
20.

What's in a name?

Tucker GT, Miners JO.

Br J Clin Pharmacol. 2011 May;71(5):785-6; author reply 787-90. doi: 10.1111/j.1365-2125.2010.03817.x. No abstract available.

21.

Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.

Guest EJ, Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT, Houston JB, Galetin A.

Br J Clin Pharmacol. 2011 Jan;71(1):72-87. doi: 10.1111/j.1365-2125.2010.03799.x.

22.

A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.

Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A.

Clin Pharmacokinet. 2010 Mar;49(3):189-206. doi: 10.2165/11318160-000000000-00000.

PMID:
20170207
24.

Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction.

Almond LM, Yang J, Jamei M, Tucker GT, Rostami-Hodjegan A.

Curr Drug Metab. 2009 May;10(4):420-32. Review.

PMID:
19519348
25.

Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power.

Johnson TN, Kerbusch T, Jones B, Tucker GT, Rostami-Hodjegan A, Milligan PA.

Pharm Stat. 2009 Jul-Sep;8(3):186-202. doi: 10.1002/pst.373.

PMID:
19291743
26.

Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.

Shiran MR, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT, Rostami-Hodjegan A.

Br J Clin Pharmacol. 2009 Jan;67(1):29-37. doi: 10.1111/j.1365-2125.2008.03312.x.

27.

The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.

O'Mathúna B, Farré M, Rostami-Hodjegan A, Yang J, Cuyàs E, Torrens M, Pardo R, Abanades S, Maluf S, Tucker GT, de la Torre R.

J Clin Psychopharmacol. 2008 Oct;28(5):523-9. doi: 10.1097/JCP.0b013e318184ff6e.

PMID:
18794647
28.

Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions.

Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A.

Curr Drug Metab. 2008 Jun;9(5):384-94. Review.

PMID:
18537575
29.

Development of CYP2D6 and CYP3A4 in the first year of life.

Johnson TN, Tucker GT, Rostami-Hodjegan A.

Clin Pharmacol Ther. 2008 May;83(5):670-1. No abstract available.

PMID:
18043691
30.

Prediction of intestinal first-pass drug metabolism.

Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A.

Curr Drug Metab. 2007 Oct;8(7):676-84. Review.

PMID:
17979655
31.

The effect of ethanol on the release of opioids from oral prolonged-release preparations.

Walden M, Nicholls FA, Smith KJ, Tucker GT.

Drug Dev Ind Pharm. 2007 Oct;33(10):1101-11.

32.

Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers.

Newell-Price J, Whiteman M, Rostami-Hodjegan A, Darzy K, Shalet S, Tucker GT, Ross RJ.

Clin Endocrinol (Oxf). 2008 Jan;68(1):130-5. Epub 2007 Sep 4.

PMID:
17803699
33.

Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes.

Perrett HF, Barter ZE, Jones BC, Yamazaki H, Tucker GT, Rostami-Hodjegan A.

Drug Metab Dispos. 2007 Oct;35(10):1733-6. Epub 2007 Jun 28.

PMID:
17600083
34.

Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems.

Van LM, Hargreaves JA, Lennard MS, Tucker GT, Rostami-Hodjegan A.

Eur J Pharm Sci. 2007 Sep;32(1):8-16. Epub 2007 May 22.

PMID:
17574396
35.

Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition.

Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A.

Eur J Pharm Sci. 2007 Jul;31(3-4):232-41. Epub 2007 Apr 25.

PMID:
17512176
36.

Misuse of the well-stirred model of hepatic drug clearance.

Yang J, Jamei M, Yeo KR, Rostami-Hodjegan A, Tucker GT.

Drug Metab Dispos. 2007 Mar;35(3):501-2. No abstract available.

PMID:
17325025
37.

The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example.

Dickinson GL, Lennard MS, Tucker GT, Rostami-Hodjegan A.

Br J Clin Pharmacol. 2007 Jul;64(1):14-26. Epub 2007 Feb 12.

38.

Simulation and prediction of in vivo drug metabolism in human populations from in vitro data.

Rostami-Hodjegan A, Tucker GT.

Nat Rev Drug Discov. 2007 Feb;6(2):140-8. Review.

PMID:
17268485
39.

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.

Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, Tucker GT, Rostami-Hodjegan A.

Curr Drug Metab. 2007 Jan;8(1):33-45. Review.

PMID:
17266522
40.
41.
42.

Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.

Johnson TN, Rostami-Hodjegan A, Tucker GT.

Clin Pharmacokinet. 2006;45(9):931-56.

PMID:
16928154
43.

Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences.

Inoue S, Howgate EM, Rowland-Yeo K, Shimada T, Yamazaki H, Tucker GT, Rostami-Hodjegan A.

Xenobiotica. 2006 Jun;36(6):499-513.

PMID:
16865818
44.

Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling.

Shiran MR, Proctor NJ, Howgate EM, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A.

Xenobiotica. 2006 Jul;36(7):567-80.

PMID:
16864504
45.

Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia.

Merza Z, Rostami-Hodjegan A, Memmott A, Doane A, Ibbotson V, Newell-Price J, Tucker GT, Ross RJ.

Clin Endocrinol (Oxf). 2006 Jul;65(1):45-50.

PMID:
16817818
46.

Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability.

Howgate EM, Rowland Yeo K, Proctor NJ, Tucker GT, Rostami-Hodjegan A.

Xenobiotica. 2006 Jun;36(6):473-97.

PMID:
16769646
47.

Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.

Yang J, Jamei M, Heydari A, Yeo KR, de la Torre R, Farré M, Tucker GT, Rostami-Hodjegan A.

J Psychopharmacol. 2006 Nov;20(6):842-9. Epub 2006 May 19.

PMID:
16714321
48.

A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation.

Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, Rostami-Hodjegan A.

Curr Drug Metab. 2006 Apr;7(3):315-34. Review.

PMID:
16611025
49.

The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).

Van LM, Heydari A, Yang J, Hargreaves J, Rowland-Yeo K, Lennard MS, Tucker GT, Rostami-Hodjegan A.

J Psychopharmacol. 2006 Nov;20(6):834-41. Epub 2006 Feb 14.

PMID:
16478752
50.

Changes in liver volume from birth to adulthood: a meta-analysis.

Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A.

Liver Transpl. 2005 Dec;11(12):1481-93.

Supplemental Content

Loading ...
Support Center